Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 2/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16239185 | 0.85 | ALDH1A1 (0.47) | TYMSKDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL16236443 | 0.85 | NPC1 (0.40) | TYMSKDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL16236256 | 0.85 | HSD17B10 (0.49) | TYMSKDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL16239279 | 0.85 | LMNA (0.43) | KDM4EHSD17B10ALDH1A1HPGDNPC1 | |
| SCHEMBL16235702 | 0.85 | LMNA (0.43) | KDM4EHSD17B10ALDH1A1HPGDTP53 | |
| SCHEMBL1958548 | 0.84 | TYMS (0.49) | TYMSKDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL16239134 | 0.81 | THRB (0.38) | KDM4EHSD17B10ALDH1A1HPGDTP53 | |
| SCHEMBL16236113 | 0.80 | TYMS (0.37) | TYMSKDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL16235591 | 0.80 | KDM4E (0.45) | KDM4EALDH1A1TP53HTTELANE | |
| SCHEMBL16236482 | 0.80 | LMNA (0.41) | TYMSKDM4EALDH1A1HPGDTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005860-B2 | Catalyst components for the polymerization of olefins | BASELL POLIOLEFINE ITALIA S.R.L. (IT) | 2018-06-26 | — | — | US | disclosed |
| EP-2997049-B1 | CATALYST COMPONENTS FOR THE POLYMERIZATION OF OLEFINS | BASELL POLIOLEFINE ITALIA SRL (IT) | 2017-08-23 | — | — | EP | disclosed |
| US-20170166667-A1 | CATALYST COMPONENTS FOR THE POLYMERIZATION OF OLEFINS | BASELL POLIOLEFINE ITALIA S.R.L. (IT) | 2017-06-15 | — | — | US | disclosed |
| US-9644051-B2 | Catalyst components for the polymerization of olefins | BASELL POLIOLEFINE ITALIA S.R.L. (IT) | 2017-05-09 | — | — | US | disclosed |
| US-20160090428-A1 | CATALYST COMPONENTS FOR THE POLYMERIZATION OF OLEFINS | Basell Poliolefine Italia, s.r.l. (IT) | 2016-03-31 | — | — | US | disclosed |
| EP-2803679-A1 | Catalyst components for the polymerization of olefins | Basell Poliolefine Italia S.r.l. (IT) | 2014-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005860-B2 | Catalyst components for the polymerization of olefins | OXER1, OXSR1, NR0B2 | TYMS 2161/4885KDM4E 4727/4885HSD17B10 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.